Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Company Financial Support Encourages Mammography Screening: J&J
December 26, 2005
- Stop the press!
December 26, 2005
- SURVEY 3 articles
December 26, 2005
- Discussions to Continue on Pricing of Long-listed Drugs, Frequency of Price Revisions
December 26, 2005
- R&D NEWS IN BRIEF
December 26, 2005
- JGPMA to Submit Petition on Full Specifications for Generics
December 26, 2005
- Outline of FY2006 NHI Pricing System Reform Approved
December 26, 2005
- 13 New Kit Products Listed
December 26, 2005
- New R&D Tax Break System to Unify 2 Existing Systems
December 26, 2005
- REGULATORY NEWS IN BRIEF -1-
December 26, 2005
- REGULATORY NEWS IN BRIEF -2-
December 26, 2005
- Blopress Retains No. 1 Ranking, Lipitor Takes No. 2 Spot
December 26, 2005
- Takeda Becomes Alfresa HD's Top Supplier
December 26, 2005
- BUSINESS NEWS IN BRIEF
December 26, 2005
- Requirements for DPC Hospitals Proposed by Korosho
December 19, 2005
- (Proposed) Direction for FY2006 NHI Pricing System Reform
December 19, 2005
- Pollinosis Much More Common in Boys Under 10 Years of Age
December 19, 2005
- Korosho's Reform Proposal Would Weaken Industry: Mr Crenshaw of PhRMA
December 19, 2005
- Airborne Cedar Pollen Levels Should Be Lower in 2006
December 19, 2005
- Long-listed Drugs' NHI Price Reductions to Negatively Affect State Finances: OPIR
December 19, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…